FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1918827992> ?p ?o ?g. }

• W1918827992 endingPage "759" @default.
• W1918827992 startingPage "751" @default.
• W1918827992 abstract "Sorafenib might prevent hepatocellular carcinoma (HCC) recurrence caused by the promotion of neoangiogenesis after transarterial chemoembolization (TACE).To evaluate the efficacy and safety of TACE followed by sorafenib for treating advanced HCC.We retrospectively analyzed 95 advanced HCC patients treated with TACE between July 2008 and December 2012 at our institution. Twenty-four patients received TACE followed by sorafenib within 14 days (S-TACE) and 71 received TACE alone. Progression-free survival (PFS) and cumulative survival from the time of non-responsiveness to TACE were compared between groups and predictive factors for PFS were analyzed.The median patient age was 72.2 years and 74 patients were male (77.9 %). Although median tumor size was similar between groups, the mean tumor number was significantly higher in the S-TACE versus TACE-alone group (16 vs. 8, P = 0.04). The number of prior treatments was significantly higher in the S-TACE group. Other baseline variables were similar. There were two severe adverse events in the S-TACE group and none in the TACE-alone group. Median PFS (189 vs. 106 days, P = 0.02) and median overall survival time (861 vs. 467 days, P = 0.01) from the time of non-responsiveness to TACE were significantly longer with S-TACE than TACE alone. Adjusting for significant factors in univariate analysis, multivariate analysis indicated that sorafenib administration, tumor size, and alanine transaminase were independent predictors of PFS.TACE followed by sorafenib significantly improved PFS and survival in patients with advanced HCC unresponsive to TACE." @default.
• W1918827992 created "2016-06-24" @default.
• W1918827992 creator A5008751771 @default.
• W1918827992 creator A5029009538 @default.
• W1918827992 creator A5031521743 @default.
• W1918827992 creator A5039237617 @default.
• W1918827992 creator A5047174570 @default.
• W1918827992 creator A5052001303 @default.
• W1918827992 creator A5074255337 @default.
• W1918827992 creator A5083295181 @default.
• W1918827992 creator A5084040015 @default.
• W1918827992 creator A5088417909 @default.
• W1918827992 date "2015-10-08" @default.
• W1918827992 modified "2023-10-01" @default.
• W1918827992 title "Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis" @default.
• W1918827992 cites W1454642722 @default.
• W1918827992 cites W1586421535 @default.
• W1918827992 cites W1634990876 @default.
• W1918827992 cites W1902459366 @default.
• W1918827992 cites W1928084746 @default.
• W1918827992 cites W1970732559 @default.
• W1918827992 cites W1971837077 @default.
• W1918827992 cites W1977161163 @default.
• W1918827992 cites W1994193851 @default.
• W1918827992 cites W1996229105 @default.
• W1918827992 cites W1996703005 @default.
• W1918827992 cites W1997533142 @default.
• W1918827992 cites W2006862071 @default.
• W1918827992 cites W2009257495 @default.
• W1918827992 cites W2011663359 @default.
• W1918827992 cites W2030567091 @default.
• W1918827992 cites W2034028376 @default.
• W1918827992 cites W2042209473 @default.
• W1918827992 cites W2043162780 @default.
• W1918827992 cites W2047554241 @default.
• W1918827992 cites W2052552898 @default.
• W1918827992 cites W2054887165 @default.
• W1918827992 cites W2055985600 @default.
• W1918827992 cites W2058887247 @default.
• W1918827992 cites W2068451863 @default.
• W1918827992 cites W2085106601 @default.
• W1918827992 cites W2089783561 @default.
• W1918827992 cites W2090748609 @default.
• W1918827992 cites W2094608386 @default.
• W1918827992 cites W2100869382 @default.
• W1918827992 cites W2102942095 @default.
• W1918827992 cites W2112716777 @default.
• W1918827992 cites W2113660458 @default.
• W1918827992 cites W2122688881 @default.
• W1918827992 cites W2123275658 @default.
• W1918827992 cites W2124101927 @default.
• W1918827992 cites W2125763116 @default.
• W1918827992 cites W2133423870 @default.
• W1918827992 cites W2135201074 @default.
• W1918827992 cites W2139248078 @default.
• W1918827992 cites W2140765540 @default.
• W1918827992 cites W2142806941 @default.
• W1918827992 cites W2154239359 @default.
• W1918827992 cites W2154907534 @default.
• W1918827992 cites W2156538729 @default.
• W1918827992 cites W2163403599 @default.
• W1918827992 cites W2168041959 @default.
• W1918827992 cites W2213448039 @default.
• W1918827992 cites W2333034220 @default.
• W1918827992 cites W2377806452 @default.
• W1918827992 cites W2591717879 @default.
• W1918827992 cites W4243625103 @default.
• W1918827992 cites W4245784696 @default.
• W1918827992 doi "https://doi.org/10.1007/s40261-015-0333-3" @default.
• W1918827992 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4969905" @default.
• W1918827992 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26728977" @default.
• W1918827992 hasPublicationYear "2015" @default.
• W1918827992 type Work @default.
• W1918827992 sameAs 1918827992 @default.
• W1918827992 citedByCount "26" @default.
• W1918827992 countsByYear W19188279922015 @default.
• W1918827992 countsByYear W19188279922016 @default.
• W1918827992 countsByYear W19188279922017 @default.
• W1918827992 countsByYear W19188279922018 @default.
• W1918827992 countsByYear W19188279922019 @default.
• W1918827992 countsByYear W19188279922020 @default.
• W1918827992 countsByYear W19188279922021 @default.
• W1918827992 countsByYear W19188279922022 @default.
• W1918827992 countsByYear W19188279922023 @default.
• W1918827992 crossrefType "journal-article" @default.
• W1918827992 hasAuthorship W1918827992A5008751771 @default.
• W1918827992 hasAuthorship W1918827992A5029009538 @default.
• W1918827992 hasAuthorship W1918827992A5031521743 @default.
• W1918827992 hasAuthorship W1918827992A5039237617 @default.
• W1918827992 hasAuthorship W1918827992A5047174570 @default.
• W1918827992 hasAuthorship W1918827992A5052001303 @default.
• W1918827992 hasAuthorship W1918827992A5074255337 @default.
• W1918827992 hasAuthorship W1918827992A5083295181 @default.
• W1918827992 hasAuthorship W1918827992A5084040015 @default.
• W1918827992 hasAuthorship W1918827992A5088417909 @default.
• W1918827992 hasBestOaLocation W19188279921 @default.
• W1918827992 hasConcept C126322002 @default.
• W1918827992 hasConcept C143998085 @default.

• next